Medtech company Allergan (NYSE:AGN) officially dumped its obesity interventions business, consummating with Apollo Endosurgery a deal worth up to $110 million.
Bariatrics
Weight loss: Docs unveil new study of bariatric surgery in teens | MassDevice.com On Call
MASSDEVICE ON CALL — Researchers this week unveiled the 1st early results from a benchmark clinical trial evaluating bariatric weight-loss surgery in severely obese adolescents.
The investigators reported "encouraging" outcomes in the more than 240 patients who were, on average, 17 years old, finding "few short-term complications" in the 30 days following treatment.
Apollo Endosurgery to buy Allergan’s obesity biz for up to $110M
Weight loss: USGI launches ambitious study of incision-free bariatric surgery
USGI Medical will enroll up to 350 patients in an FDA-approved clinical trial of the g-Cath EZ suture anchor delivery catheter, an incision-free bariatric surgery technology that has already been used on more than 2,000 patients, mostly in Europe.
Reimbursement process begins in Switzerland, Germany for GI Dynamics’ EndoBarrier
GI Dynamics (ASX:GID) said Swiss and German regulators took the 1st steps toward reimbursement in those countries for its EndoBarrier weight loss and diabetes device.
Can we bypass the bypass to treat diabetes?
Gastric bypass surgery creates a small pouch in the stomach and connects it directly to the small intestine. Why does it help type 2 diabetes? (Wikimedia Commons)
Diabetes: GI Dynamics pulls in $35M tranche in $52M round
GI Dynamics (ASX:GID) said it’s pulled in nearly $35 million as part of a $52 million funding round it’s planning to use to back a U.S. trial of its EndoBarrier device.
The Lexington, Mass.-based medical device company said in a regulatory filing that it’s drummed up $34.8 million from 13 unnamed investors.
Weight loss: GI Dynamics raises $52M, announces share purchase plan
GI Dynamics (ASX:GID) said it’s raised roughly $52.2 million (A$57.5 million) in a private placement and is offering another $2.3 million (A$2.5 million) in a stock purchase plan for existing shareholders.
Weight loss: France bankrolls EndoBarrier cost trial for GI Dynamics
French regulators will fund a trial looking at the cost and utility of the EndoBarrier device for Type II diabetes and weight loss made by GI Dynamics (ASX:GID).
Weight loss: GI Dynamics adds centers in Europe
GI Dynamics (ASX:GID) said another 5 medical centers in Europe are online with its EndoBarrier weight loss and diabetes device.
The Lexington, Mass.-based medical device company said centers in Spain, Switzerland and 3 in Germany are now implanting the device, a gut liner designed to inhibit the uptake of nutrients from food.
Chris Christie, Dick Cheney and the power of celebrity endorsements for medical devices
When the New York Post broke the story this week that New Jersey governor and presidential hopeful Chris Christie had underwent weight loss surgery using the LAP-BAND in February some on Wall Street bemoaned the rotund politicians timing.